Abstracts tagged "Abatacept"

Abstract Number: 458 • 2015 ACR/ARHP Annual Meeting
First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network
Boulos Haraoui¹, Louis Coupal², Radmila Day³, Lionel Budry⁴ and Youb Chalabi⁵, ¹Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ³None, Montreal, QC, Canada, ⁴Bristol Myers Squibb Canada, St-Laurent, QC, Canada, ⁵Bristol Myers Squibb, Montreal, QC, Canada
Background/Purpose: The subcutaneous (SC) formulation of abatacept (ABA) has been available in Canada since January 2014. Here we report first year experience with SC ABA…
Abstract Number: 2733 • 2015 ACR/ARHP Annual Meeting
Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis
Kazuhiro Otani¹, Haruyasu Ito¹, Kenichiro Hirai², Kentaro Noda², Ken Yoshida², Isamu Kingetsu² and Daitaro Kurosaka², ¹Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: Telomere is a component of chromosome, and protects end of chromosome from various stress. Telomere shortens during cell division, and telomerase maintains telomere length.…
Abstract Number: 459 • 2015 ACR/ARHP Annual Meeting
The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry
Ihsan Ertenli¹, Omer Karadag¹, Yavuz Pehlivan², Ediz Dalkilic³, Ahmet Mesut Onat⁴, Bunyamin Kisacik⁵, Gercek Can⁶, Servet Akar⁷, Sedat Capar⁸, Umut Kalyoncu¹, Mustafa Ferhat Oksuz⁹, Emine Figen Tarhan⁷ and Nurullah Akkoc⁶, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, ⁷Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁸Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁹Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Abatacept (ABA) is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). In TURKBIO, Turkish Biologic Registry, data on patient characteristics, diagnosis, previous treatment…
Abstract Number: 2735 • 2015 ACR/ARHP Annual Meeting
Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li², E Alemao³, S Deveikis¹ and J Kremer⁵, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: It has been postulated that patients with longstanding RA have more treatment-resistant disease. We propose to examine whether disease duration is an independent predictor…
Abstract Number: 471 • 2015 ACR/ARHP Annual Meeting
Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titer on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab
Jeremy Sokolove¹, M Schiff², Roy Fleischmann³, Michael Weinblatt⁴, SE Connolly⁵, A Johnsen⁵, J Zhu⁵, MA Maldonado⁵, S Patel⁵ and WH Robinson⁶, ¹Stanford University School of Medicine, Palo Alto, CA, ²University of Colorado, Denver, CO, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In patients (pts) with RA, the predictive value of baseline (BL) titers of anti-citrullinated protein antibodies (ACPA), a known biomarker for RA and disease…
Abstract Number: 2740 • 2015 ACR/ARHP Annual Meeting
ACPA Positivity in the Elderly and Concomitant MTX Use in Younger May be Useful Predictive Factors for Superior Clinical Efficacy with Abatacept in Japanese Biological-Naïve RA Patients
Masahiro Sekiguchi¹, Takao Fujii², Masayasu Kitano¹, Kiyoshi Matsui¹, Kenji Miki³, Hideo Hashimoto⁴, Akira Yokota⁵, Aihiro Yamamoto⁶, Takashi Fujimoto⁷, Toshihiko Hidaka⁸, Naoki Shimmyo⁹, Keiji Maeda¹⁰, Takanori Kuroiwa¹¹, Ichiro Yoshii¹², Kosaku Murakami¹³, Koichiro Ohmura¹³, Satoshi Morita¹⁴, Yutaka Kawahito⁶, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁶ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Dept of Rheum/Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁴Rheumatology, Rinku Hashimoto Rheumatology Orthopaedics, Izumisano Osaka, Japan, ⁵Yokota Clinic for Rheumatology, Osaka, Japan, ⁶Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁷Nara Medical University, Kashihara, Japan, ⁸Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ⁹Department of Rheumatology, Kashiba Asahigaoka Hospital, Kashiba, Japan, ¹⁰Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ¹¹Department of Internal Medicine, Yukioka Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Rheumatology & Clin Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁴Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Osaka Rheumatology Clinic, Osaka, Japan, ¹⁶Dept of Rheum & Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Sustained clinical remission is crucial in the RA. However, baseline predicting factors for sustained clinical remission in RA patients treated with abatacept (ABT) are…
Abstract Number: 488 • 2015 ACR/ARHP Annual Meeting
Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: The sustainability of any regimen is an important factor to consider when selecting therapy for chronic conditions, such as rheumatoid arthritis (RA). Recent reports…
Abstract Number: 501 • 2014 ACR/ARHP Annual Meeting
Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register
Carl Turesson¹, Leszek Stawiarz², Staffan Lindblad³ and Saedis Saevarsdottir⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
Abstract Number: 2923 • 2014 ACR/ARHP Annual Meeting
Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis
A Obry^1,2, P Cosette², T Lequerré^1,3, Maria-Antonietta d'Agostino⁴, C Gaillez⁵, M Le Bars⁶ and O Vittecoq^1,3, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²UMR 6270 CNRS, PISSARO Proteomic Facility, IRIB, Normandy University, University of Rouen, Rouen, France, ³Department of Rheumatology, Rouen University Hospital, Rouen, France, ⁴AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Targeted biologic therapies with different mechanisms of action are commonly used in RA. Abatacept is a recombinant fusion protein that inhibits T-cell co-stimulatory molecules…
Abstract Number: 516 • 2014 ACR/ARHP Annual Meeting
The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study
Shinya Hirabara¹, Toshihisa Kojima², Nobunori Takahashi², Yuji Hirano¹, Atsushi Kaneko³, Daihei Kida⁴, Yasuhide Kanayama⁵ and Naoki Ishiguro², ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, ⁵Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often…
Abstract Number: 2504 • 2014 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT), a selective co-stimulation modulator, is the first in a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that…
Abstract Number: 510 • 2014 ACR/ARHP Annual Meeting
Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept – Results from the National Swedish Rheumatology Quality Register
Carl Turesson¹, Leszek Stawiarz², Staffan Lindblad³ and Saedis Saevarsdottir⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
Abstract Number: 2492 • 2014 ACR/ARHP Annual Meeting
Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study
H Nüßlein¹, R Alten², M Galeazzi³, HM Lorenz⁴, MT Nurmohamed⁵, WG Bensen⁶, Gerd Burmester⁷, H-H Peter⁸, P Peichl⁹, K Pavelka¹⁰, M Chartier¹¹, C Poncet¹², C Rauch¹³ and M Le Bars¹⁴, ¹Internistische Schwerpunktpraxis, Nürnberg, Germany, ²Schlosspark-Klinik University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵VU Univ Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Charité-Universitätsmedizin, Berlin, Germany, ⁸University of Freiburg, Freiburg, Germany, ⁹Evangelisches Krankenhaus, Vienna, Austria, ¹⁰Institute of Rheumatology, Charles University, Prague, Czech Republic, ¹¹Chiltern International, Neuilly, France, ¹²Docs International, Nanterre, France, ¹³Bristol-Myers Squibb, Munich, Germany, ¹⁴Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In RA, reduced efficacy with anti-TNF therapy1 and dose escalation2 have been reported for obese patients (pts) compared with non-obese pts. Clinical trials have…
Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting
First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis
Tristan Pascart¹, Rene-Marc Flipo², Xavier Deprez³ and Eric Houvenagel⁴, ¹Rheumatology, Saint-Philibert Hospital, Lille, France, ²Rheumatology, University Hospital Lille, Lille, France, ³Rhumatologie, Ch De Valenciennes, Valenciennes, France, ⁴Rheumatology, Saint-Philibert Hospital, LOMME, France
Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…
Abstract Number: 2486 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis
Daniel E. Furst¹, Vivian P. Bykerk², Gerd Burmester³, B Combe⁴, T W J Huizinga⁵, E Alemao⁶, D Wong⁶, C S Karyekar⁶ and P Emery⁷, ¹University of California at Los Angeles, Los Angeles, CA, ²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Monpellier University Hospital, Montpellier, France, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Early biologic use can improve long-term control of RA,1,2 potentially leading to improved physical function and reduced pain. Recent EULAR recommendations support shared decisions…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].